Market Research Logo

Neuromodulation Devices Global Market – Forecast To 2021

Neuromodulation Devices Global Market – Forecast To 2021

The neuromodulation technology utilizes devices that bring about a change in nervous system either by stimulation or modulating brain activity. The treatment delivered by neuromodulation devices brings about life changing transformation in patients who fail to get better by traditional approaches. The opportunities to development new therapies for a wide variety of neurological and psychological conditions are attracting lot of companies, start ups and investments. According to IQ4I analysis, the global neuromodulation devices market is expected to grow at a double digit CAGR to reach $9.3 billion by 2021. Factors driving the neuromodulation market include, projected increase in patients with chronic pain, neurodegenerative diseases, psychiatric conditions, improvements in technology such as miniaturization, better battery technology, use of bioactive coatings are all contributing for growth of neuromodulation devices market whereas risk of side effects, availability of alternative treatment and high initial cost of implants are the factors hampering the market growth. Advancement of technology with its wide application areas shows that neuromodulation devices market has vast opportunities in the coming years.

Neuromodulation devices market is segmented on the basis of technology as internal and external neuromodulation. The internal neuromodulation is again classified into Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), Sacral Nerve Stimulation (SNS) and Other with Gastric Electric Stimulation (GES) and Respiratory Electrical Stimulation (RES)/Phrenic Nerve Stimulation (PNS). Based on the application the neuromodulation devices market is segmented into Chronic Pain, Movement Disorders, Psychiatric Conditions, Gastroenterology & Urology and other applications. Based on end-users the market is segmented into hospitals and private neuromodulation clinics.

North America accounts for the highest market share of 56.1% followed by Europe. Steep rise in ageing population, advancement in technology, awareness of people and favourable government policies makes U.S. the leader of neuromodulation devices market. However, Asian countries especially India and China are the fast growing regions with its growing demand for neuromodulation devices.

Major players in Neuromodulation devices market include Medtronic (Ireland), Boston Scientific (U.S.), Cyberonics (U.S.), St. Jude Medical (U.S.), Neurometrix, Inc (U.S.), Neuronetics, Inc (U.S.), Nevro Corporation (U.S.), Synapse Biomedical (U.S.), Avery Biomedical (U.S.) and Magstim (U.K.).

The report provides an in depth market analysis of the above mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)


1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKE AWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 PRIMARY SOURCES
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNTIES
3.3.1.1 Aging population and increase in chronic diseases such as Parkinson’s and Alzheimer’s disorders.
3.3.1.2 Low approval rate and Cuts in R&D budget of CNS drugs to drive neuromodulation market
3.3.1.3 Emergence of neuromodulation as add on therapy
3.3.1.4 Technology innovations and increased investments in neuromodulation.
3.3.1.5 Expansion in Emerging markets
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Side effects and risks associated with the use
3.3.2.2 Availability of alternative treatments
3.3.3 BURNING ISSUE
3.3.3.1 Lack of trained professionals
3.4 REGULATORY AFFAIRS
3.4.1 U.S.
3.4.2 EUROPE
3.4.3 CHINA
3.4.4 CANADA
3.4.5 INDIA
3.5 REIMBURSEMENT SCENARIO
3.6 PATENT ANALYSIS
3.7 TECHNOLOGICAL ADVANCEMENTS
3.7.1 RECHARGEABLE SYSTEMS
3.7.2 OPTOGENETIC TECHNOLOGY
3.7.3 ULTRASONIC STIMULATION
3.7.4 MINIATURIZATION
3.7.5 PORTABLE NUEROMODULATION SYSTEMS (PONS)
3.7.6 WEARABLE PAIN MANAGEMENT TECHNOLOGY
3.7.7 TRANS-SPINAL DIRECT CURRENT STIMULATION (TSDCS)
3.7.8 NANO-NEUROMODULATION
3.7.9 BIOACTIVE COATINGS
3.8 UPCOMING TECHNOLOGIES
3.9 PORTER’S FIVE FORCE ANALYSIS
3.9.1 THREAT OF NEW ENTRANTS
3.9.2 THREAT OF SUBSTITUTES
3.9.3 BARGAINING POWER OF SUPPLIERS
3.9.4 BARGAINING POWER OF BUYERS
3.9.5 RIVALRY AMONG EXISTING COMPETITORS
3.10 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
4 NEUROMODULATION DEVICES GLOBAL MARKET, BY TECHNOLOGY
4.1 INTRODUCTION
4.2 INTERNAL NEUROMODULATION
4.2.1 SPINAL CORD STIMULATION (SCS)
4.2.2 DEEP BRAIN STIMULATION (DBS)
4.2.3 VAGUS NERVE STIMULATION (VNS)
4.2.4 SACRAL NERVE STIMULATION (SNS)
4.2.5 OTHERS
4.2.5.1 Gastric electric stimulation (GES)
4.2.5.2 Respiratory electrical stimulation (RES)/Phrenic nerve stimulation
4.3 EXTERNAL NEUROMODULATION
4.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
4.3.2 TRANSCRANIAL MAGNETIC STIMULATION (TMS)
5 GLOBAL NEUROMODULATION DEVICES MARKET, BY APPLICATIONS
5.1 INTRODUCTION
5.2 CHRONIC PAIN
5.2.1 FAILED BACK SURGERY SYNDROME (FBSS)
5.2.2 ISCHEMIA
5.2.3 MIGRAINE
5.3 MOVEMENT DISORDERS
5.3.1 PARKINSON’S DISEASE
5.3.2 ESSENTIAL TREMORS
5.3.3 DYSTONIA
5.3.4 EPILEPSY OR SEIZURE
5.4 PSYCHIATRIC CONDITION
5.4.1 DEPRESSION
5.4.2 OBSESSIVE COMPULSIVE DISORDER (OCD)
5.5 GASTROENTEROLOGY AND UROLOGY
5.5.1 GASTROPARESIS
5.5.2 URINARY INCONTINENCE
5.5.3 FAECAL INCONTINENCE
5.6 OTHERS
5.6.1 OBESITY
5.6.2 DIAPHRAGM PACING
6 NEUROMODULATION DEVICES GLOBAL MARKET, BY END-USERS
6.1 INTRODUCTION
6.2 HOSPITALS
6.3 PRIVATE CLINICS/THERAPY CENTERS
7 REGIONAL ANALYSIS
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.3 EUROPE
7.4 ASIA- PACIFIC
7.5 REST OF THE WORLD
8 COMPANY DEVELOPMENTS
8.1 INTRODUCTION
8.2 APPROVALS
8.3 AGREEMENTS & COLLOBORATIONS
8.4 NEW PRODUCT LAUNCHES
8.5 MERGERS & ACQUISITIONS
8.6 OTHERS
9 COMPANY PROFILES
9.1 AVERY BIOMEDICAL DEVICES, INC
9.1.1 OVERVIEW
9.1.2 FINANCIALS
9.1.3 PRODUCT PORTFOLIO
9.1.4 KEY DEVELOPMENTS
9.1.5 BUSINESS STRATEGIES
9.1.6 SWOT ANALYSIS
9.2 BOSTON SCIENTIFIC CORPOARTION
9.2.1 OVERVIEW
9.2.2 FINANCIALS
9.2.3 PRODUCT PORTFOLIO
9.2.4 KEY DEVELOPMENTS
9.2.5 BUSINESS STRATEGY
9.2.6 SWOT ANALYSIS
9.3 COGENTIX MEDICAL (UROPLASTY, INC)
9.3.1 OVERVIEW
9.3.2 FINANCIALS
9.3.3 PRODUCT PORTFOLIO
9.3.4 KEY DEVELOPMENTS
9.3.5 BUSINESS STRATEGY
9.3.6 SWOT ANALYSIS
9.4 CYBERONICS, INC (LIVANOVA)
9.4.1 OVERVIEW
9.4.2 FINANCIALS
9.4.3 PRODUCT PORTFOLIO
9.4.4 KEY DEVELOPMENTS
9.4.5 BUSINESS STRATEGY
9.4.6 SWOT ANALYSIS
9.5 MAGSTIM COMPANY LTD
9.5.1 OVERVIEW
9.5.2 FINANCIALS
9.5.3 PRODUCT PORTFOLIO
9.5.4 SERVICES
9.5.5 KEY DEVELOPMENTS
9.5.6 BUSINESS STRATEGIES
9.5.7 SWOT ANALYSIS
9.6 MEDTRONIC, PLC
9.6.1 OVERVIEW
9.6.2 FINANCIALS
9.6.3 PRODUCT PORTFOLIO
9.6.4 KEY DEVELOPMENTS
9.6.5 BUSINESS STRATEGY
9.6.6 SWOT ANALYSIS
9.7 NEUROMETRIX, INC
9.7.1 OVERVIEW
9.7.2 FINANCIALS
9.7.3 PRODUCT PORTFOLIO
9.7.4 KEY DEVELOPMENTS
9.7.5 BUSINESS STRATEGY
9.7.6 SWOT ANALYSIS
9.8 NEURONETICS, INC
9.8.1 OVERVIEW
9.8.2 FINANCIALS
9.8.3 PRODUCT PORTFOLIO
9.8.4 KEY DEVELOPMENTS
9.8.5 BUSINESS STRATEGY
9.8.6 SWOT ANALYSIS
9.9 NEUROPACE, INC,
9.9.1 OVERVIEW
9.9.2 FINANCIALS
9.9.3 PRODUCT PORTFOLIO
9.9.4 KEY DEVELOPMENTS
9.9.5 BUSINESS STRATEGIES
9.9.6 SWOT ANALYSIS
9.10 NEVRO CORPORATION
9.10.1 OVERVIEW
9.10.2 FINANCIALS
9.10.3 PRODUCT PORTFOLIO
9.10.4 KEY DEVELOPMENTS
9.10.5 BUSINESS STRATEGY
9.10.6 SWOT ANALYSIS
9.11 ST. JUDE MEDICAL, INC
9.11.1 OVERVIEW
9.11.2 FINANCIALS
9.11.3 PRODUCT PORTFOLIO
9.11.4 KEY DEVELOPMENTS
9.11.5 BUSINESS STRATEGY
9.11.6 SWOT ANALYSIS
9.12 SYNAPSE BIOMEDICAL, INC
9.12.1 OVERVIEW
9.12.2 FINANCIALS
9.12.3 PRODUCT PORTFOLIO
9.12.4 KEY DEVELOPMENTS
9.12.5 BUSINESS STRATEGY
9.12.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 2 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 3 INTERNAL NEUROMODULATION GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 4 INTERNAL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 5 SPINAL CORD STIMULATION (SCS) GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 6 DEEP BRAIN STIMULATION (DBS) GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 7 VAGUS NERVE STIMULATION (VNS) GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 8 SACRAL NERVE STIMULATION GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 9 OTHERS INTERNAL NEUROMODULATION GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 10 EXTERNAL NEUROMODULATION GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 11 EXTERNAL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE,
BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 12 TENS NEUROMODULATION GLOBAL MARKET REVENUE, BY REGION,
(2013-2021) ($MN)
TABLE 13 TMS NEUROMODULATION GLOBAL MARKET REVENUE, BY REGION,
(2013-2021) ($MN)
TABLE 14 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY APPLICATION, (2013-2021) ($MN)
TABLE 15 CHRONIC PAIN GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 16 MOVEMENT DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 17 PSYCHIATRIC DISORDERS GLOBAL MARKET REVENUE, BY REGION,
(2013-2021) ($MN)
TABLE 18 GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 19 OTHERS NEUROMODULATION STIMULATION GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 20 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY END-USERS, (2013-2021) ($MN)
TABLE 21 HOSPITALS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 22 PRIVATE CLINICS/THERAPY CENTERS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 23 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
TABLE 24 NORTH AMERICAN NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 25 NORTH AMERICAN INTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 26 NORTH AMERICAN EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 27 NORTH AMERICAN NEUROMODULATION DEVICES MARKET REVENUE, BY APPLICATION, (2013-2021) ($MN)
TABLE 28 NORTH AMERICAN NEUROMODULATION DEVICES MARKET REVENUE, BY END USER, (2013-2021) ($MN)
TABLE 29 EUROPEAN NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 30 EUROPEAN INTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 31 EUROPEAN EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 32 EUROPEAN NEUROMODULATION DEVICES MARKET REVENUE, BY APPLICATION, (2013-2021) ($MN)
TABLE 33 EUROPEAN NEUROMODULATION DEVICES MARKET REVENUE, BY END USER, (2013-2021) ($MN)
TABLE 34 ASIA-PACIFIC NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 35 ASIA-PACIFIC INTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 36 ASIA PACIFIC EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 37 ASIA-PACIFIC NEUROMODULATION DEVICES MARKET REVENUE,
BY APPLICATION, (2013-2021) ($MN)
TABLE 38 ASIA-PACIFIC NEUROMODULATION DEVICES MARKET REVENUE,
BY END USER, (2013-2021) ($MN)
TABLE 39 ROW NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 40 ROW INTERNAL NEUROMODULATION DEVICES MARKET REVENUE,
BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 41 ROW EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE,
BY TECHNOLOGY, (2013-2021) ($MN)
TABLE 42 ROW NEUROMODULATION DEVICES MARKET REVENUE, BY APPLICATION, (2013-2021) ($MN)
TABLE 43 ROW NEUROMODULATION DEVICES MARKET REVENUE, BY END USER, (2013-2021) ($MN)
TABLE 44 APPROVALS (2013-2015)
TABLE 45 AGREEMENT AND COLLABORATION (2013-2015)
TABLE 46 NEW PRODUCT LAUNCHES (2013-2015)
TABLE 47 MERGERS & ACQUISTIONS (2013-2015)
TABLE 48 OTHERS (2013-2015)
TABLE 49 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
TABLE 50 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE BY SEGMENTS, (2012-14) ($MN)
TABLE 51 BOSTON SCIENTIFIC CORPORATION: MEDSURG REVENUE, BY SEGMNETS (2012-2014) ($MN)
TABLE 52 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE BY GEOGRAPHY (2012-2014) ($MN)
TABLE 53 COGENTIX MEDICAL: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
TABLE 54 COGENTIX MEDICAL: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
TABLE 55 CYBERONICS, INC: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
TABLE 56 CYBERONICS, INC: TOTAL REVENUE BY GEOGRAPHY (2012-2014) ($MN)
TABLE 57 MEDTRONIC, PLC : TOTAL REVENUE AND R&D EXPENSES,
(2012-2014) ($MN)
TABLE 58 MEDTRONIC, PLC: TOTAL REVENUE, BY SEGMENTS, (2012-2014) ($MN)
TABLE 59 MEDTRONIC, PLC: RESTORATIVE THERAPY REVENUE, BY SUB-SEGMENTS, (2012-2014) ($MN)
TABLE 60 MEDTRONIC, PLC: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
TABLE 61 NEUROMETRIX : TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
TABLE 62 NEUROMETRIX: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
TABLE 63 NEUROMETRIX: TOTAL REVENUE BY PRODUCTS, (2012-14) ($MN)
TABLE 64 NEVRO CORP.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
TABLE 65 NEVRO CORP: TOTAL REVENUE BY GEOGRAPHY, (2012-2014) ($MN)
TABLE 66 ST. JUDE MEDICAL, INC: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
TABLE 67 ST. JUDE MEDICAL, INC: TOTAL REVENUE BY SEGMENTS, (2012-14) ($MN)
TABLE 68 ST. JUDE MEDICAL, INC: TOTAL REVENUE BY GEOGRAPHY, (2012-2014) ($MN)
LIST OF FIGURES
FIGURE 1 NEUROMODULATON DEVICES GLOBAL MARKET REVENUE, BY REGION (2013-2021) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: NEUROMODULATION DEVICES GLOBAL MARKET
FIGURE 3 NEUROMODULATION DEVICES MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 NEUROMODULATION DEVICES MARKET: FORECASTING MODEL
FIGURE 5 NEUROMODULATION DEVICES MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 6 NEUROMODULATION DEVICES MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 NEUROMOUDLATION DEVICES MARKET:PCT APPLICATIONS FILING BY MAJOR PLAYERS (2011-2015)
FIGURE 9 NEUROMODULATION DEVICES MARKET: PORTER’S ANALYSIS
FIGURE 10 GLOBAL NEUROMODULATION DEVICES MARKET SHARE, BY MAJOR PLAYERS (2014)
FIGURE 11 NEUROMODULATION DEVICES GLOBAL REVENUE, BY TECHNOLOGY (2014 V’S 2021) ($MN)
FIGURE 12 INTERNAL NEUROMODULATION DEVICES GLOBAL REVENUE, BY TECHNOLOGY (2014 V’S 2021) ($MN)
FIGURE 13 EXTERNAL NEUROMODULATION DEVICES GLOBAL REVENUE, BY TECHNOLOGY (2014 V’S 2021) ($MN)
FIGURE 14 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY APPLICATION (2014 V’S 2021) ($MN)
FIGURE 15 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY END USERS (2014 V’S 2021) ($MN)
FIGURE 16 NEUROMODULATON DEVICES GLOBAL MARKET REVENUE, BY REGION (2013-2021) ($MN)
FIGURE 17 NORTH AMERICAN NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, APPLICATION & END-USER (2014 V’S 2021) ($MN)
FIGURE 18 EUROPEAN NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, APPLICATION & END-USER (2014 V’S 2021) ($MN)
FIGURE 19 ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, APPLICATION & END-USER (2014 V’S 2021) ($MN)
FIGURE 20 ROW NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, APPLICATION & END-USER (2014 V’S 2021) ($MN)
FIGURE 21 KEY GROWTH STRATEGIES (2013-2015)
FIGURE 22 SWOT: AVERY BIOMEDICAL DEVICES, INC
FIGURE 23 SWOT: BOSTON SCIENTIFIC CORPORATION
FIGURE 24 SWOT: COGENTIX MEDICAL
FIGURE 25 SWOT: CYBERONICS, INC
FIGURE 26 SWOT: MAGSTIM COMPANY LIMITED
FIGURE 27 SWOT: MEDTRONIC, PLC
FIGURE 28 SWOT: NEUROMETRIX, INC
FIGURE 29 SWOT: NEURONETICS, INC
FIGURE 30 SWOT: NEUROPACE, INC
FIGURE 31 SWOT: NEVRO CORP
FIGURE 32 SWOT: ST. JUDE MEDICAL, INC
FIGURE 33 SWOT: SYNAPSE BIOMEDICAL, INC

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report